Open AccessAntiproliferative activity from Aldama arenaria (Baker) E. E. Schill. & Panero
Author(s) -
Adriana da Silva Santos de Oliveira,
Paulo M. Imamura,
Ana L. T. G. Ruiz,
Beatriz AppezzatodaGlória,
Tuane de Oliveira,
Vera Lúcia Garcia
Publication year - 2021
Publication title -
boletín latinoamericano y del caribe de plantas medicinales y aromáticas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.218
H-Index - 21
ISSN - 0717-7917
DOI - 10.37360/blacpma.21.20.1.4
Subject(s) - in vitro , ovary , melanoma , chemistry , in vivo , pharmacology , cell culture , traditional medicine , biology , medicine , cancer research , biochemistry , genetics , microbiology and biotechnology
Chloroform extract (CE) and fractions obtained from Aldama arenaria roots were evaluated for their in vitro antiproliferative activity against 10 human tumor cell lines [leukemia (K-562), breast (MCF-7), ovary expressing a multidrug-resistant phenotype (NCI/ADR-RES), melanoma (UACC-62), lung (NCI-H460), prostate (PC-3), colon (HT29), ovary (OVCAR-3), glioma (U251), and kidney (786-0)]. CE presented weak to moderate antiproliferative activity (mean log GI50 1.07), whereas fractions 3 and 4, enriched with pimarane-type diterpenes [ent-pimara-8(14),15-dien-19-oic acid and ent-8(14),15-pimaradien-3β-ol], presented moderate to potent activity for most cell lines, with mean log GI50 of 0.62 and 0.59, respectively. The results showed promising in vitro antiproliferative action of the samples obtained from A. arenaria, with the best results for NCI/ADR-RES, HT29, and OVCAR-3, and TGI values ranging from 5.95 to 28.71 µg.mL-1, demonstrating that compounds of this class may be potential prototypes for the discovery of new therapeutic agents.